Biotechnology Form D filings.
432 Form D notices were filed in the Biotechnology industry group in Q2 2026 and Q3 2026, 363 new and 69 amendments. 94.2% claimed Rule 506(b) and 5.6% Rule 506(c).
- Notices
- 432
- Amendments
- 69
- Rule 506(c)
- 5.6%
- Pooled funds
- 1.2%
- Amount sold, new notices
- $4.16B
- Latest filing
- 2026-09-30
Latest notices
| Filed | Issuer | Location | Type | Amount sold | Offering size | Exemptions |
|---|---|---|---|---|---|---|
| 2026-09-30 | Autology, Inc. | Ohio | D | $3.4M | $5.1M | Rule 506(b) |
| 2026-09-29 | Sialia Therapeutics, Inc. | California | D | $1.5M | $1.5M | Rule 506(b) |
| 2026-09-29 | HAWKHILL THERAPEUTICS Ltd | United Kingdom | D/A | $291K | $291K | Rule 506(b) |
| 2026-09-29 | Conexeu Sciences Inc. | Nevada | D | $31K | $31K | Rule 506(b) |
| 2026-09-29 | GENHEALTH, INC. | Virginia | D | $16.5M | $16.5M | Rule 506(b) |
| 2026-09-29 | Vetmab Biosciences, Inc. | California | D | $11.4M | $11.9M | Rule 506(b) |
| 2026-09-29 | GT Biopharma, Inc. | California | D | $7.8M | $39.0M | Rule 506(b) |
| 2026-09-28 | Xact Bio, Inc. | Massachusetts | D | $10.0M | $18.0M | Rule 506(b) |
| 2026-09-28 | Pace Pharmaceuticals, Inc. | California | D | $50K | Indefinite | Rule 506(c) |
| 2026-09-28 | Q-Immune, Inc. | Washington | D | $25K | $1.0M | Rule 506(b) |
| 2026-09-28 | Pictura Bio US, Inc. | United Kingdom | D | $9.1M | $17.5M | Rule 506(b) |
| 2026-09-28 | Pictura Bio US, Inc. | United Kingdom | D | $15.0M | $15.0M | Rule 506(b) |
| 2026-09-28 | Vertical Longevity Pharmaceuticals, Inc. | California | D | $110K | $110K | Rule 506(b) |
| 2026-09-28 | Evia Bio, Inc. | Minnesota | D | $5.5M | $5.5M | Rule 506(b) |
| 2026-09-25 | Way Biosolutions, Inc. | Massachusetts | D | $2.0M | $2.0M | Rule 506(b) |
| 2026-09-25 | EyeMacular Regeneration, Inc. | Minnesota | D/A | $2.9M | $6.0M | Rule 506(b) |
| 2026-09-25 | OptoVista Holdings, LLC | District Of Columbia | D | $3.7M | $3.7M | Rule 506(c) |
| 2026-09-25 | Navigator Medicines, Inc. | California | D | $10.0M | $40.0M | Rule 506(b) |
| 2026-09-25 | AutoIVF, Inc. | Massachusetts | D | $1.5M | $1.5M | Rule 506(b) |
| 2026-09-25 | EnteroTrack, LLC | Colorado | D | $2.0M | $2.0M | Rule 506(b) |
| 2026-09-24 | Argonaute RNA Ltd | United Kingdom | D | $1.8M | $1.8M | Rule 506(b) |
| 2026-09-24 | Swift Cardiovascular, Inc. | North Carolina | D | $810K | $1.5M | Rule 506(b) |
| 2026-09-24 | Seraxis Holdings, Inc. | Maryland | D | $10.0M | $10.0M | Rule 506(b) |
| 2026-09-23 | Uvantis Therapeutics, Inc. | Maryland | D | $100K | $5.0M | Rule 506(b) |
| 2026-09-23 | DIGITAL ETHER COMPUTING, LLC | Florida | D/A | $625K | $2.0M | Rule 506(b) |
| 2026-09-23 | SalivIQ Diagnostics Inc. | Virginia | D/A | $1.9M | $3.2M | Rule 506(b) |
| 2026-09-23 | Hera Biotech, Inc. | Texas | D/A | $1.7M | $5.0M | Rule 506(b) |
| 2026-09-23 | Caspian Therapeutics, Inc. | California | D | $50.0M | $50.0M | Rule 506(b) |
| 2026-09-23 | Biophytis SA | France | D | $2.6M | $2.6M | Rule 506(b) |
| 2026-09-22 | Opus Medical Therapies, LLC | Georgia | D | $485K | Indefinite | Rule 506(b) |
Median minimum investment accepted, among the 6 notices above that report one: $50,000.
Query these notices
The Form D offerings endpoint returns every notice for a quarter with all issuer identities and source strings. Filter by issuer CIK, or page through a quarter and group by industry or location yourself.
curl "https://sec-api.dev/api/v1/offerings?period=2026q3&limit=25" \
-H "Authorization: Bearer $SEC_API_KEY"Questions
How many Form D filings were in Biotechnology?
432 Form D notices were filed in the Biotechnology industry group in Q2 2026 and Q3 2026, 363 new and 69 amendments. 94.2% claimed Rule 506(b) and 5.6% Rule 506(c).
Does amount sold equal money raised this quarter?
No. The total amount sold on a notice is cumulative for the offering. Use new notices, or the latest amendment per offering, to avoid double counting.
Other industries
Plain-text version for agents and LLMs: /form-d/industries/biotechnology.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.